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Abstract:
By triggering an adaptive response to hypoxia which is a common feature of tumor
microenvironments, endothelial cells contribute to the onset of angiogenic responses involved in
tumor growth. Therefore, identifying hypoxic markers represent a challenge for a better understanding
of tumor angiogenesis and for the optimization of anti-angiogenic therapeutic strategy. Using
Representational Difference Analysis combined with microarray, we here report the identification of
133 hypoxia-induced transcripts in human microendothelial cells (HMEC-1). By Northern Blot, we
confirm hypoxia-induced expression of Insulin-like growth factor binding protein 3 (igfbp3),
thioredoxin-interacting protein (txnip), neuritin (nrn1). Finally, by performing in situ hybridization on
several types of human tumors, we provide evidence for nrn1 and txnip as hypoxic perinecrotic
markers and for igfbp3 as a tumor endothelial marker. We propose these hypoxia-induced genes could
represent relevant prognostic tools and targets for therapeutic intervention in cancers.
Keywords: angiogenesis, hypoxia, endothelial cells, gene expression, tumor markers
List of abbreviations: HMEC-1, Human MicroEndothelial Cells 1; IGFBP3, Insulin-like growth
factor binding protein 3; TXNIP, thioredoxin-interacting protein; NRN1, neuritin
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1. Introduction:
By exercising control over gene transcription, hypoxia is a common feature of several human
pathologies, including cardiovascular diseases and cancer. In solid tumors, the balance between cell
proliferation and oxygen supply is affected, leading to a decrease in oxygen partial pressure (pO2) [1].
Hypoxic cells trigger an adaptative molecular response to modulate expression of many genes in order
to allow better perfusion and (pO2) increase in tumor tissue. Hypoxia-induced gene expression is
under the control of key-transcription factors, the Hypoxia-Inducible Factors (HIFs) [2], involving
posttranslational modifications of the -subunit which determine both half-life and transcriptional
activity on target genes [3,4].
Angiogenesis promotes not only tumor growth, but also progression from a pre-malignant to a
malignant and invasion tumor phenotype. In the tumor microenvironment, hypoxia appears to target a
multiplicity of cell types which participate in tumor progression and endothelial cells are widely
involved in tumor angiogenesis. In this context, targeting the tumor vasculature to « normalize » it [5]
temporarily or to eradicate it completely seems to be a promising anti-cancer therapeutic strategy [6].
To this aim, gene expression profiles of tumor cells [7] but also of endothelial cells in response to
hypoxia were characterized by using microarray technologies or differential screening techniques [8-
11]. However, new markers are needed for a better understanding of the hypoxia-induced angiogenesis
in tumors and for the development of new diagnostic, prognostic and therapeutic tools in cancer [8].
Here, we first report a novel repertoire of hypoxia-induced transcripts (HITs) in human
microendothelial cells HMEC-1 using mRNA differential screening by cDNA Representational
Difference Analysis (cDNA RDA) [12] and cDNA microarray. We then described mRNA expression
of HITs, particularly Neuritin (nrn1), Thioredoxin-interacting protein (txnip) and Insulin-like growth
factor binding protein 3 (igfbp3), in various types of human tumors. Based on these observations, we
therefore propose these HITs might represent relevant prognostic tools and targets for therapeutical
intervention in cancers.
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2. Material and Methods:
Cell culture and tissues
Primary cultures of HUVEC at passage 3 were cultured in EGM-2 medium (Cambrex) with 2% FBS
and HMEC-1 (human dermal microvasvular endothelial cells, a gift from Thomas J. Lawley, Emory
University, School of Medicine, Atlanta, GA) maintained as previously described. For hypoxic
treatments, cells were grown in an atmosphere containing 2% O2, in an IG750 incubator (Jouan,
France), or in the presence of 100 µmol/L of DFO for 20 hours.
All tumor tissues were obtained from the Pathological Anatomy Department of Tenon Hospital (Paris,
France). Tissues were fixed in 20% formaldehyde and embedded in paraffin. Human tumors were
classified according to the revised World Health Organization criteria for tumors.
RNA isolation and cDNA synthesis
Total RNA was isolated from HMEC-1 and HUVEC cultured in hypoxic and normoxic conditions
using the RNeasy midiprep kit from Qiagen. RNA was digested with RNase-free DNase RQ1
(Promega) for 30 minutes and 10 µg of poly(A)+ RNA, prepared by performing the Oligotex mRNA
kit (Qiagen) procedures twice, were used to synthesize double-stranded cDNA using oligodT priming
and Superscript II (Invitrogen).
cDNA Representational Difference Analysis
Representational difference analysis of cDNAs was performed as described previously [12] with
several important modifications [13,14]. Subtracted RDA products were inserted into the pGEM-T
cloning vector (Promega) and analyzed by sequencing. Classification of the HITS was performed
according to S.O.U.R.C.E. database [15].
Gene expression analysis
The cDNA microarray was constructed by combining both the HITs obtained by the cDNA RDA and
the cDNA library described by Steenman et al. [16]. cDNA microarray construction and hybridization
was performed as in Steenman et al. [16]. Data were pre-processed with MADSCAN [17]. To
normalize intensity values the rank invariant method was used [18]. This method selects invariant
gene reporters on which a nonlinear regression method (lowess fitness) is applied to calculate the
normalization correction factor [19]. The identification of genes with statistically significant
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differential expression between the two populations of cells was performed using the limma R package
[20]. False discovery rate (FDR) correction was applied to take into account multiple testing
hypotheses. Significance levels were set to p<0.05 and p<0.01. Genes below these thresholds were
considered significantly differentially expressed.
Northern Blots were performed using NorthernMax kit from Ambion. Briefly, 20µg/lane of total RNA
was fractionated by 1% denaturing gel electrophoresis and transferred to nylon membranes (Hybond
N
+
 ; Amersham Biosciences). The blots were hybridized with 
32
P-labeled cDNA probes (Random
Primer DNA Labeling System ; Invitrogen) overnight at 42°C in the UltraHyb solution (Ambion).
Paraffin section preparation, probe labeling by in vitro transcription, and in situ hybridization were
performed as previously described [14].
Immunohistochemistry
Immunostaining with a polyclonal goat anti-human IGFBP3 (1/50; R&D Systems AF675) antibody
was performed by routine methods using a biotinylated secondary antibody and the ABC-peroxidase
complex (Vector Laboratories) with diaminobenzidine-H2O2 used as the chromogen for detection.
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3. Results and Discussion:
In order to identify genes whose expression is induced by hypoxia in endothelial cells, we
performed a differential screening by cDNA Representational Difference Analysis between HMEC-1
cells, the first immortalized endothelial cells which retains the main characteristics of primary
endothelial cells, cultured in normoxia (20% O2) or in the presence of the iron chelator desferoxamine,
thus mimicking hypoxia for 20 hours. Both normoxic and hypoxic cDNA libraries are prepared and
three successive rounds of hybridization/PCR amplification were performed allowing to obtain
cDNAs which are overexpressed in hypoxia compared to normoxia. 1000 clones were subsequently
sequenced and 300 non-redundant cDNA fragments were identified. These HITs were used for
creating a cDNA microarray slide which was then hybridized with cDNAs from HMEC-1 cultured
either in chemical (DFO 100 M), gazeous (2% O2) hypoxia or normoxia for 20 hours. The data were
subjected to statistical analysis allowing the identification of 131 genes overexpressed in endothelial
cells (ECs) cultured under chemical hypoxia, of which 57 are also induced by gazeous hypoxia (see
supplementary material, table 1). 77% were annotated genes and 23% left were ESTs or
hypothetical proteins. Classification of RDA-induced genes according to S.O.U.R.C.E. confirmed
most cellular functions are regulated by hypoxia. Indeed, consistent with previous observations, we
observed the increased expression of genes which are involved in cellular metabolism, including
glycolysis genes (tpi1, g3pdb, hk2, eno1, ldha) and glucose transporters (glut3). We further confirmed
a large number of genes, such as txnip, igfbp3 and angptl4, which have already been shown to be
overexpressed in primary endothelial cell lines as HUVECs, HAECs and HPAECs in previous
transcriptome studies using various approaches [8-11]. Interestingly, we provided evidence for new
endothelial HITs such as neuritin, neuroleukin, stk25, csnk1e and snrk, plectin and cortactin involved
in neurogenesis/neuritogenesis, signal transduction and cytoskeletal organisation respectively.
In order to further confirm hypoxia induction, we performed Northern Blot analysis on
HMEC-1 and HUVEC cultured in hypoxic conditions, specifically for the pro-apoptotic gene igfbp3,
the tumor and metastasis suppressor gene txnip and the firstly described hypoxia-induced gene
neuritin1 (nrn1). Normalization of the genes of interest to a housekeeping gene, such as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), -actin or cyclophilin could not be
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performed here since the fact that steady-state levels of these control genes cannot be assumed in
endothelial cells exposed to DFO or 2% hypoxia. Therefore, the amounts of RNA loaded were
normalized by hybridization with a 28S-specific probes which is known to be a constant fraction
of total RNA. We observed hypoxia-induced expression of these 3 genes in both endothelial cell
types, namely HMEC-1 and HUVEC, subjected to chemical hypoxia compared to normoxia, as
previously shown for angptl4 [14], used as a control here. Lowering oxygen concentration also
induced expression of igfbp3 and nrn1 in both HMEC-1 and HUVEC while level of expression was
less important than using DFO. Txnip mRNA was not detected in HUVEC and only very weakly in
HMEC-1 cells cultured in gaseous hypoxic conditions (figure 1). DFO as an iron chelator used at
100µM might be more efficient than gazeous hypoxia at 2% O2 on PHD and FIH inactivation and
might enhance transcription via HIF-, which could explain differences between chemical and
gazeous hypoxia-induced gene expressions. HIF-prolylhydroxylases (PHD1-3) and Factor Inhibiting
HIF (FIH) are enzymes belonging to 2-oxoglutarate and Fe(II) dependent dioxygenases superfamily.
They are involved in HIF- proteasome degradation and transcription suppression by hydroxylation of
oxygen-dependent degradation domain (ODDD) and C-Terminal Transactivation Domain (C-TAD)
respectively and have iron (Fe
2+
), 2-oxoglutarate and dioxygen as co-substrates [4].
Given that both tumor and vascular cells were shown to be hypoxic in tumors, we then studied
the expression of these HITs in various types of human cancers with the aim to characterize new tumor
and/or tumor endothelial markers. In the present study, we focused on nrn1, txnip and igfbp3 for
which no or only few data were available concerning their in situ mRNA expression in cancers.
Neuritin, also called CPG15, is a GPI-anchored protein which was reported to be weakly
expressed in human kidney, heart, spleen, lung [21]. Neuritin is also expressed in the liver and is
well correlated to the maturation of hepatocytes [22] as well as in neuronal structures associated
with plasticity in the adult [21]. NRN1 has been largely involved in neuritogenesis and was shown to
promote dendritic growth [23] and the development of motor neuron axon arbors [24]. In this study,
we demonstrated that nrn1 gene is expressed and induced by hypoxia in ECs. Neuritin could therefore
belong to the increasing family of axon guidance which could be implicated in vessel pathfinding and
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network formation as recently shown for several of these molecules [25]. To the best of our
knowledge, nrn1 mRNA expression has never been described in human biopsies from normal or
tumor tissues. Here, by performing in situ hybridization experiments, we examined nrn1 mRNA
expression in different human tumors such as colon and prostate tumors, renal cell carcinoma and
glioblastoma. Nrn1 is expressed in both tumor and normal epithelial cells and weakly in endothelia of
blood vessels of normal and tumoral areas in colon and prostate (data not shown). For the first time,
we showed that nrn1 mRNA is reproducibly highly expressed in a restricted number of tumor cells
around perinecrotic regions of conventional RCC (figure 2: a-c) and glioblastoma (figure 2: d-f),
regions in which hypoxia has been reported to up-regulate gene expression [26]. We did not detect
nrn1 expression in peritumoral areas of these two types of tumor (data not shown). Furthermore,
NRN1 has recently been implicated in tumorigenesis by promoting changes in cell morphology,
anchorage-independent growth and tumor formation [27]. In this context, the fact that hypoxic tumor
cells highly express neuritin makes this molecule an attractive candidate as a hypoxic tumor marker
and a potential target for therapeutic intervention in cancers.
Thioredoxin-interacting protein is interacting and negatively regulating thioredoxin [28] and is
involved in suppression of tumor growth [29]. Furthermore, in an in vitro model of intravasation,
overexpression of TXNIP by infecting melanoma cells with adenovirus increased transendothelial
migration 3-fold versus control [30]. Until now, txnip mRNA was reported to be downregulated in
various human tumors, including breast, stomach and lung [29] and gastrointestinal cancers [31]. For
the first time, we provide evidence for txnip overexpression in tumor cells of hypoxic perinecrotic
areas of conventional RCC (figure 2: g-i) and glioblastoma (figure 2: j-l) compared to non-hypoxic
tumor cells and peritumoral tissues. Furthermore, hypoxia is often associated with increased
metastasis and poor prognosis in cancer. Therefore, txnip might represent a valid candidate as
prognostic marker and therapeutic target for anti-metastatic treatment.
We also studied IGFBP3 expression, which is shown to have anti-IGF-1 and IGF-1-
independent pro-apoptotic activities. Many studies have provided evidence for the in vitro induction of
igfbp3 mRNA by hypoxia in different cell types, including ES cells [32], tumor cells [7,33] and ECs
[9,11,34]. In vivo, a marked increase of igfbp3 mRNA was reported in the endothelium of human
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corpus luteum during early phase of luteal development which is accompanied by extensive
angiogenesis [35] and specifically in tumor endothelial cells of a murine breast cancer model [36]. We
here provide evidence for an igfbp3 mRNA expression in intratumoral ECs of colon carcinoma (figure
3: a-c), whereas tumor and normal epithelial cells of the colon don’t express igfbp3 mRNA (data not
shown). Concerning prostate, we showed that igfbp3 is also very highly expressed in the ECs of
adenocarcinoma (figure 3: d-f). We also demonstrated that igfbp3 mRNA is specifically produced by
ECs of tumor blood vessels in conventional RCC classified as pT1 in tumor, node, metastasis (TNM)
system. In contrast, to draw a conclusion from results obtained in patients with pT2 and pT3
conventional RCC is more difficult. Indeed, igfbp3 mRNA is produced only by tumor cells in some
patients whereas expressed by both tumor cells and intratumor ECs in some other patients (data not
shown). Finally, igfbp3 mRNA expression was investigated in chromophobe RCC. Accordingly, a
very high level of igfbp3 mRNA was observed only in ECs of tumor vessels, but not in tumor cells, of
all patients with chromophobe RCC (figure 3 : j-l). Interestingly, igfbp3 mRNA was not detected in
peritumoral kidney of any renal tumor (data not shown). We further characterized IGFBP3 protein
expression in these tumors by immunohistochemistry. IGFBP3 was detected in ECs of tumor vessels,
but neither in tumor cells nor in tubular cells of peritumoral region, within clear-cell and chromophobe
RCC (figure 4: a and b respectively). These results are in accordance with previous in vitro study
showing a very weak expression in primary proximal tubular cells and primary renal cell
carcinoma [37]. IGFBP3 is also expressed in peritumoral ECs of these tumors and in some tumor
cells of chromophobe RCC. We further demonstrated a similar pattern of IGFBP3 staining in blood
vessels of colon and prostate tumors (figure 4 : c and d respectively), with a high expression level in
both tumor endothelium as well as in peritumoral ECs close to the tumor. We therefore characterize
igfbp3 gene as an endothelial marker in various human tumors. Recently, it was shown that IGFBP3
reverses proliferation and prevents the survival induced by VEGF in HUVEC [38] and that
downregulation of endothelial igfbp3 mRNA by Runx1 transcription factor promoted angiogenesis in
the matrigel assay [39]. However, IGFBP3 functions in tumor-associated angiogenesis are not
understood yet and have to be examined thoroughly in order to evaluate IGFBP3 suitability as a valid
therapeutic target. The present study compared nrn1, txnip and igfbp3 mRNAs expression in
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tumor and peritumoral area. Data concerning the expression of these genes in human biopsies
from normal organs (kidney, colon, prostate) are lacking in the litterature. Therefore, more
detailed gene expression analyses have to be performed on normal tissues to fully consider nrn1,
txnip and igfbp3 as proper tumor markers.
Altogether, this work provided evidence for a new set of hypoxia-induced genes in ECs in
vitro. Overexpression of some of these genes was further observed in different cell types subjected to
in vivo pathological hypoxia, particularly in tumor cells surrounding necrotic regions or tumor
endothelial cells. In this context, we propose these genes, txnip, nrn1 and igfbp3 as hypoxic markers
and potential makers in tumor angiogenesis, might become prognostic tools and potential anti-
cancerous therapeutic targets.
4. Acknowledgements
We thank Dr. Mathilde Sibony (Pathological Anatomy Department of Tenon Hospital, Paris,
France) for providing all tumor tissues. SLJ is a recipient of both Ministère de la Recherche and
Fondation pour la Recherche Médicale fellowships. AC is a recipient of an INSERM fellowship. SG is
supported by grants from la Fondation de France and Canceropole-PACA ACI 2004 and belongs to
the European Vascular Genomics Network (http://www.evgn.org) a Network of Excellence supported
by the European Community's sixth Framework Programme for Research Priority 1 "Life sciences,
genomics and biotechnology for health" (Contract N° LSHM-CT-2003-503254).
- 10 -
5. References:
[1] Helmlinger, G., Yuan, F., Dellian, M. and Jain, R.K. (1997). Interstitial pH and pO2 gradients
in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 3,
177-82.
[2] Semenza, G.L. (1998). Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr
Opin Genet Dev. 8, 588-94.
[3] Brahimi-Horn, C., Mazure, N. and Pouyssegur, J. (2005). Signalling via the hypoxia-inducible
factor-1alpha requires multiple posttranslational modifications. Cell Signal. 17, 1-9.
[4] Masson, N. and Ratcliffe, P.J. (2003). HIF prolyl and asparaginyl hydroxylases in the
biological response to intracellular O(2) levels. J Cell Sci. 116, 3041-9.
[5] Jain, R.K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic
therapy. Science. 307, 58-62.
[6] Folkman, J. (1972). Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg.
175, 409-16.
[7] Lal, A., Peters, H., St Croix, B., Haroon, Z.A., Dewhirst, M.W., Strausberg, R.L., Kaanders,
J.H., van der Kogel, A.J. and Riggins, G.J. (2001). Transcriptional response to hypoxia in
human tumors. J Natl Cancer Inst. 93, 1337-43.
[8] St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A.,
Riggins, G.J., Lengauer, C., Vogelstein, B. and Kinzler, K.W. (2000). Genes expressed in
human tumor endothelium. Science. 289, 1197-202.
[9] Scheurer, S.B., Rybak, J.N., Rosli, C., Neri, D. and Elia, G. (2004). Modulation of gene
expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and
proteomic study. Proteomics. 4, 1737-60.
[10] Ning, W., Chu, T.J., Li, C.J., Choi, A.M. and Peters, D.G. (2004). Genome-wide analysis of
the endothelial transcriptome under short-term chronic hypoxia. Physiol Genomics. 18, 70-8.
[11] Manalo, D.J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B.D., Ye, S.Q., Garcia, J.G. and
Semenza, G.L. (2005). Transcriptional regulation of vascular endothelial cell responses to
hypoxia by HIF-1. Blood. 105, 659-69.
- 11 -
[12] Hubank, M. and Schatz, D.G. (1999). cDNA representational difference analysis: a sensitive
and flexible method for identification of differentially expressed genes. Methods Enzymol.
303, 325-49.
[13] Pastorian, K., Hawel, L., 3rd and Byus, C.V. (2000). Optimization of cDNA representational
difference analysis for the identification of differentially expressed mRNAs. Anal Biochem.
283, 89-98.
[14] Le Jan, S., Amy, C., Cazes, A., Monnot, C., Lamande, N., Favier, J., Philippe, J., Sibony, M.,
Gasc, J.M., Corvol, P. and Germain, S. (2003). Angiopoietin-like 4 is a proangiogenic factor
produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 162, 1521-8.
[15] Diehn, M., Sherlock, G., Binkley, G., Jin, H., Matese, J.C., Hernandez-Boussard, T., Rees,
C.A., Cherry, J.M., Botstein, D., Brown, P.O. and Alizadeh, A.A. (2003). SOURCE: a unified
genomic resource of functional annotations, ontologies, and gene expression data. Nucleic
Acids Res. 31, 219-23.
[16] Steenman, M., Lamirault, G., Le Meur, N., Le Cunff, M., Escande, D. and Leger, J.J. (2005).
Distinct molecular portraits of human failing hearts identified by dedicated cDNA
microarrays. Eur J Heart Fail. 7, 157-65.
[17] Le Meur, N., Lamirault, G., Bihouee, A., Steenman, M., Bedrine-Ferran, H., Teusan, R.,
Ramstein, G. and Leger, J.J. (2004). A dynamic, web-accessible resource to process raw
microarray scan data into consolidated gene expression values: importance of replication.
Nucleic Acids Res. 32, 5349-58.
[18] Tseng, G.C., Oh, M.K., Rohlin, L., Liao, J.C. and Wong, W.H. (2001). Issues in cDNA
microarray analysis: quality filtering, channel normalization, models of variations and
assessment of gene effects. Nucleic Acids Res. 29, 2549-57.
[19] Yang, Y.H., Dudoit, S., Luu, P., Lin, D.M., Peng, V., Ngai, J. and Speed, T.P. (2002).
Normalization for cDNA microarray data: a robust composite method addressing single and
multiple slide systematic variation. Nucleic Acids Res. 30, e15.
[20] Smyth, G.K. (2004) in: Statistical Applications in Genetics and Molecular Biology, Vol. 3:
No. 1, Article 3.
- 12 -
[21] Naeve, G.S., Ramakrishnan, M., Kramer, R., Hevroni, D., Citri, Y. and Theill, L.E. (1997).
Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis.
Proc Natl Acad Sci U S A. 94, 2648-53.
[22] Kojima, N., Shiojiri, N., Sakai, Y. and Miyajima, A. (2005). Expression of neuritin during
liver maturation and regeneration. FEBS Lett. 579, 4562-6.
[23] Nedivi, E., Wu, G.Y. and Cline, H.T. (1998). Promotion of dendritic growth by CPG15, an
activity-induced signaling molecule. Science. 281, 1863-6.
[24] Javaherian, A. and Cline, H.T. (2005). Coordinated motor neuron axon growth and
neuromuscular synaptogenesis are promoted by CPG15 in vivo. Neuron. 45, 505-12.
[25] Eichmann, A., Le Noble, F., Autiero, M. and Carmeliet, P. (2005). Guidance of vascular and
neural network formation. Curr Opin Neurobiol. 15, 108-15.
[26] Onita, T., Ji, P.G., Xuan, J.W., Sakai, H., Kanetake, H., Maxwell, P.H., Fong, G.H., Gabril,
M.Y., Moussa, M. and Chin, J.L. (2002). Hypoxia-induced, perinecrotic expression of
endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with
tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin
Cancer Res. 8, 471-80.
[27] Raggo, C., Ruhl, R., McAllister, S., Koon, H., Dezube, B.J., Fruh, K. and Moses, A.V. (2005).
Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-
associated herpesvirus. Cancer Res. 65, 5084-95.
[28] Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y.,
Sono, H., Gon, Y. and Yodoi, J. (1999). Identification of thioredoxin-binding protein-
2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and
expression. J Biol Chem. 274, 21645-50.
[29] Han, S.H., Jeon, J.H., Ju, H.R., Jung, U., Kim, K.Y., Yoo, H.S., Lee, Y.H., Song, K.S.,
Hwang, H.M., Na, Y.S., Yang, Y., Lee, K.N. and Choi, I. (2003). VDUP1 upregulated by
TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle
progression. Oncogene. 22, 4035-46.
- 13 -
[30] Cheng, G.C., Schulze, P.C., Lee, R.T., Sylvan, J., Zetter, B.R. and Huang, H. (2004).
Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells.
Exp Cell Res. 300, 297-307.
[31] Ikarashi, M., Takahashi, Y., Ishii, Y., Nagata, T., Asai, S. and Ishikawa, K. (2002). Vitamin
D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to
stage of disease. Anticancer Res. 22, 4045-8.
[32] Feldser, D., Agani, F., Iyer, N.V., Pak, B., Ferreira, G. and Semenza, G.L. (1999). Reciprocal
positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer
Res. 59, 3915-8.
[33] Koong, A.C., Denko, N.C., Hudson, K.M., Schindler, C., Swiersz, L., Koch, C., Evans, S.,
Ibrahim, H., Le, Q.T., Terris, D.J. and Giaccia, A.J. (2000). Candidate genes for the hypoxic
tumor phenotype. Cancer Res. 60, 883-7.
[34] Tucci, M., Nygard, K., Tanswell, B.V., Farber, H.W., Hill, D.J. and Han, V.K. (1998).
Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by
hypoxia in cultured vascular endothelial cells. J Endocrinol. 157, 13-24.
[35] Fraser, H.M., Lunn, S.F., Kim, H. and Erickson, G.F. (1998). Insulin-like growth factor
binding protein-3 mRNA expression in endothelial cells of the primate corpus luteum. Hum
Reprod. 13, 2180-5.
[36] Schmid, M.C., Bisoffi, M., Wetterwald, A., Gautschi, E., Thalmann, G.N., Mitola, S.,
Bussolino, F. and Cecchini, M.G. (2003). Insulin-like growth factor binding protein-3 is
overexpressed in endothelial cells of mouse breast tumor vessels. Int J Cancer. 103, 577-86.
[37] Cheung, C.W., Vesey, D.A., Nicol, D.L. and Jonhson, D.W. (2004). The roles of IGF-I and
IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation.
Kidney int. 65, 1272-79.
[38] Franklin, S.L., Ferry, R.J., Jr. and Cohen, P. (2003). Rapid insulin-like growth factor (IGF)-
independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol
Metab. 88, 900-7.
- 14 -
[39] Iwatsuki, K., Tanaka, K., Kaneko, T., Kazama, R., Okamoto, S., Nakayama, Y., Ito, Y.,
Satake, M., Takahashi, S.I., Miyajima, A., Watanabe, T. and Hara, T. (2005). Runx1 promotes
angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene.
24, 1129-37.
- 15 -
6. Figure legends:
Figure 1 : Confirmation of cDNA microarray by Northern Blot analysis. Total RNA from HMEC-1
and HUVEC cultured in normoxia or hypoxia (100µM DFO or 2% O2) were fractionated on a
formaldehyde agarose gel, transferrred to a nylon membrane and probed with 
32
P-labeled probes for
igfbp3, nrn1, txnip and angptl4 mRNAs.
Figure 2 : Nrn1 and Txnip, markers of perinecrotic regions in conventional RCC and glioblastoma.
Bright field (left and right) and dark field (middle) views of nrn1 and txnip mRNA production in
perinecrotic region of conventional RCC (a-c and g-i respectively) and glioblastoma (d-f and j-l
respectively). N, necrosis area . Scale bars, 50µm.
Figure 3 : Igfbp3 mRNA, a tumor endothelial marker in various types of human tumors. HES (left),
dark field (middle) and bright field (right) views of igfbp3 mRNA expression in endothelial cells of
colon adenocarcinoma (a-c), prostate adenocarcinoma (d-f), conventional RCC (g-i) and chromophobe
RCC (j-l). Scale bars, 50µm.
Figure 4 : Characterization of IGFBP3 protein expression in human tumors. Immunostaining for
IGFBP3 protein in conventional (a) and chromophobe (b) RCC, in colon and prostate adenocarcinoma
(c and d respectively). Scale bars, 50µm.
Supplementary data : table 1
Accession 
Number
Symbol Full Name
DFO 
Fold 
change
GAZ 
Fold 
change
Difference between 
DFO and GAZ       
AF202636 ANGPTL4 angiopoietin-like 4 2,68 1,89 **
 K03021 unknown Human tissue plasminogen activator (PLAT) gene, complete cds 1,73 1,26 *
AF028593 JAG1 jagged 1 (Alagille syndrome) 1,35 - -
M14083 SERPINE1 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1,28 - -
AK025195 ROBO4 roundabout homolog 4, magic roundabout (Drosophila) 1,16 - -
M84150 LOX lysyl oxidase 2,48 1,78 *
U90441 P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II 1,93 - -
AB023207 CHSY1 carbohydrate (chondroitin) synthase 1 1,78 1,62 -
M10905 FN1 fibronectin 1 1,74 1,34 **
X54131 PTPRB protein tyrosine phosphatase, receptor type, B 1,6 1,3 *
XM_031617 THBS1 thrombospondin 1 1,53 1,42 -
M76729 COL5A1 collagen, type V, alpha 1 1,4 - -
J05593 HUMTIMP2 Human metalloproteinase-2 inhibitor (TIMP-2) mRNA, complete cds 1,39 - -
Y00815 PTPRF protein tyrosine phosphatase, receptor type, F 1,35 - -
NM_002318 LOXL2 lysyl oxidase-like 2 1,3 - -
E10341 unknown cDNA encoding human pro-cathepsin B. 1,15 - -
AF004162 NDRG1 N-myc downstream regulated gene 1 2,77 1,21 **
XM_038124 IGFBP3 insulin-like growth factor binding protein 3 1,77 1,52 -
M59465 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1,67 1,21 **
X76104 DAPK1 death-associated protein kinase 1 1,64 1,53 -
S79639 EXT1 exostoses (multiple) 1 1,60 1,41 -
AB016794 HD huntingtin (Huntington disease) 1,53 - -
M12783 PDGFB platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) 1,53 1,42 -
U23946 RBM5 RNA binding motif protein 5 1,35 - -
HSU97519 unknown Homo sapiens podocalyxin-like protein mRNA, complete cds 1,20 - -
U41635 unknown Human OS-9 precurosor mRNA, complete cds 1,16 - -
M98343 CTTN cortactin 2,58 1,58 **
AY480044 PLEC1 plectin 1, intermediate filament binding protein 500kDa 2,39 1,6 *
L29139 unknown Homo sapiens myosin mRNA, partial cds. 1,47 1,21 *
AF262992 SPAG4 sperm associated antigen 4 1,40 - -
NM_002476 MYL4 myosin, light polypeptide 4, alkali; atrial, embryonic 1,36 - -
AF195661 C16orf5 Homo sapiens transmembrane protein I1 (I1) mRNA, complete cds 1,25 - -
M64571 MAP4 microtubule-associated protein 4 1,23 - -
M96803 SPTBN1 spectrin, beta, non-erythrocytic 1 1,21 - -
HSU94352 unknown Human manic fringe precursor mRNA, complete cds 1,68 - -
NM_005566 LDHA lactate dehydrogenase A 2,91 1,84 **
M61829 MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 2,53 1,88 **
HSU18197 unknown Human ATP:citrate lyase mRNA, complete cds 2,41 1,83 *
M14328 ENO1 enolase 1, (alpha) 2,1 1,2 **
HSU79775 unknown Homo sapiens NNP-1/Nop52 (NNP-1) mRNA, complete cds 1,99 1,25 **
M17851 HUMG3PDB Human glyceraldehyde-3-phosphate dehydrogenase mRNA, complete cds 1,74 - -
BC009885 TPI1 triosephosphate isomerase 1 1,74 1,22 **
M22349 ENO2 enolase 2 (gamma, neuronal) 1,71 1,32 **
AF109735 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 1,68 1,22 **
S73849 VLDLR very low density lipoprotein receptor 1,57 - -
Z46376 unknown H.sapiens HK2 mRNA for hexokinase II. 1,43 - -
NM_000961 PTGIS prostaglandin I2 (prostacyclin) synthase 1,41 1,2 **
M64098 HDLBP high density lipoprotein binding protein (vigilin) 1,33 - -
M57638 ASL argininosuccinate lyase 1,3 1,16 -
AF136631 NRN1 neuritin 1 1,73 1,52 -
K03515 HUMNLK Human neuroleukin mRNA, complete cds 1,44 - -
Y10976 DPYSL4 dihydropyrimidinase-like 4 1,43 - -
U02389 PRSS15 protease, serine, 15 1,27 - -
AF054185 PSMA7 proteasome (prosome, macropain) subunit, alpha type, 7 1,21 - -
AF161542 CYLD cylindromatosis (turban tumor syndrome) 1,18 - -
S73591 TXNIP thioredoxin interacting protein 1,85 1,31 **
E06719 unknown cDNA encoding human protein disulfide isomerase. 1,72 - -
NM_003299 TRA1 tumor rejection antigen (gp96) 1 1,49 - -
D83174 SERPINH1 serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) 1,30 - -
U65785 HYOU1 hypoxia up-regulated 1 = ORP150 1,27 - -
Protein Folding/ Stress-induced protein
Neurogenesis/ Neuritogenesis
Protein catabolism
Table 1: Chemically and gazeous hypoxia-induced genes in HMEC-1. Hypoxia-induced genes identified by cDNA RDA were used to create a dedicated cDNA 
microarray. This cDNA microarray was then hybridized with cDNA from HMEC-1 cultured in normoxia or hypoxia (DFO or 2% O2). Statistical analysis was 
performed and difference of gene expression between DFO and gaz was analysed ( - : non significatively different; * : p<0,05; ** : p<0,01).
Angiogenesis
Cell adhesion/ Cell migration
Development
Metabolism (lipid, carbohydrates, glycolysis …)
Cell growth/ Maintenance/ Apoptosis:
Cell Structure
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S46950 ADORA2A adenosine A2a receptor 3,71 2,62 *
D63780 STK25 serine/threonine kinase 25 (STE20 homolog, yeast) 2,17 1,39 **
XM_051522 CMKOR1 chemokine orphan receptor 1 1,40 - -
AB020704 PPFIA4 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 1,38 1,19 -
U42390 TRIO triple functional domain (PTPRF interacting) 1,38 - -
BC006490 CSNK1E casein kinase 1, epsilon 1,38 - -
X12794 NR2F6 nuclear receptor subfamily 2, group F, member 6 1,35 - -
AF240696 WSB1 WD repeat and SOCS box-containing 1 1,27 1,53 -
AB003476 AKAP12 A kinase (PRKA) anchor protein (gravin) 12 1,21 - -
AK026945 TRIB3 tribbles homolog 3 (Drosophila) 1,14 - -
AF226044 SNRK SNF-1 related kinase 1,14 - -
HSU67784 unknown Human orphan G protein-coupled receptor (RDC1) mRNA, partial cds - 1,35 -
XM_018359 POM121 POM121 membrane glycoprotein (rat) 3,63 2,48 **
M20681 SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 2,35 1,62 *
X79353 GDI1 GDP dissociation inhibitor 1 2,14 1,61 *
AF274889 unknown Homo sapiens glucose transporter 3 gene, exons 1 to 6. 1,79 1,4 -
XM_036096 PTTG1IP pituitary tumor-transforming 1 interacting protein 1,71 - -
HSU10362 unknown Human GP36b glycoprotein mRNA, complete cds 1,6 - -
M23115 ATP2A2 ATPase, Ca&#43;&#43; transporting, cardiac muscle, slow twitch 2 1,29 - -
AF155652 KCMF1 potassium channel modulatory factor 1 1,19 - -
AJ011021 KCNG2 potassium voltage-gated channel, subfamily G, member 2 1,18 1,21 -
U41518 AQP1 aquaporin 1 (channel-forming integral protein, 28kDa) 1,17 - -
Z18956 SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 1,16 - -
HSU39400 unknown Homo sapiens NOF1 mRNA, complete cds 1,40 - -
AF164622 GOLGIN-67 golgin-67 1,38 1,31 -
M19997 EEF2 eukaryotic translation elongation factor 2 1,20 - -
HSU31501 unknown Human fragile X mental retardation syndrome related protein (FXR2) mRNA, complete cds 1,15 - -
AF168990 GTPBP2 GTP binding protein 2 1,15 - -
D87735 RPL14 ribosomal protein L14 - 1,17 -
HSU79775 unknown Homo sapiens NNP-1/Nop52 (NNP-1) mRNA, complete cds 1,99 1,25 **
AF159047 unknown Rattus norvegicus SPANK-2 mRNA, partial cds 1,54 - -
BC002602 UREB1 upstream regulatory element binding protein 1 1,52 1,31 -
AF070657 GSTK1 glutathione S-transferase kappa 1 1,48 - -
XM_042302 unknown Homo sapiens similar to Gene 33/Mig-6 (H. sapiens) (LOC148460),mRNA. 1,47 1,21 *
X97324 unknown H.sapiens mRNA for adipophilin 1,35 - -
AK023521 FER1L4 fer-1-like 4 (C. elegans) 1,35 1,45 -
XM_051925 LBH likely ortholog of mouse limb-bud and heart gene 1,32 - -
AF240786 GSTT2 glutathione S-transferase theta 2 1,30 - -
D87078 PUM2 pumilio homolog 2 (Drosophila) 1,28 - -
 X82209 HSMN1 Homo sapiens mRNA for MN1 protein 1,25 - -
AB020718 CLSTN1 calsyntenin 1 1,22 - -
AB028965 OIP106 OGT(O-Glc-nac transferase)-interacting protein 106 KDa 1,13 - -
BG747444 unknown 602704739F1 NIH_MGC_15 Homo sapiens cDNA clone IMAGE:4858161 5',mRNA sequence. 5,03 3,63 *
AK001776 C20orf20 Homo sapiens cDNA FLJ10914 fis, clone OVARC1000212 3,43 1,89 **
HSM800927 unknown Homo sapiens mRNA; cDNA DKFZp586N0721 (from clone DKFZp586N0721) 3,25 2,53 -
AL117505 unknown Homo sapiens mRNA; cDNA DKFZp434E1835 (from clone DKFZp434E1835). 2,81 1,89 **
BC007540 LOC144097 hypothetical protein BC007540 2,17 2,07 -
HSM801483 unknown Homo sapiens mRNA; cDNA DKFZp434E0121 (from clone DKFZp434E0121) 2,11 1,77 -
AK000885 unknown Homo sapiens cDNA FLJ10023 fis, clone HEMBA1000608, moderatelysimilar to HYPOTHETICAL PROTEIN KIAA0411. 2,03 1,41 *
AW956598 unknown EST368653 MAGE resequences, MAGD Homo sapiens cDNA, mRNA sequence. 1,91 - -
AF334711 unknown Homo sapiens C1ORF12 mRNA, 3' untranslated region, partialsequence. 1,83 1,30 **
AK021598 unknown Homo sapiens cDNA FLJ11536 fis, clone HEMBA1002712. 1,64 1,55 -
AK001196 KIAA0676 KIAA0676 protein 1,55 1,41 -
AB033023 FLJ10201 hypothetical protein FLJ10201 1,49 - -
AL117505 unknown Homo sapiens mRNA; cDNA DKFZp434E1835 (from clone DKFZp434E1835) 1,47 - -
AL118774 unknown DKFZp761B0811_r1 761 (synonym: hamy2) Homo sapiens cDNA cloneDKFZp761B0811 5', mRNA sequence. 1,46 1,39 -
AF007128 unknown Homo sapiens clone 23870 mRNA sequence. 1,44 1,27 -
AL034417 unknown Human DNA sequence from clone CTA-215D11 on chromosome 1p36.12-36.33, complete sequence 1,44 - -
AB002365 KIAA0367 KIAA0367 1,43 - -
AB020721 FAM13A1 Homo sapiens mRNA for KIAA0914 protein, partial cds 1,40 1,20 *
AW955980 unknown EST368050 MAGE resequences, MAGD Homo sapiens cDNA, mRNA sequence. 1,33 1,18 *
AF086150 unknown Homo sapiens full length insert cDNA clone ZB44E06. 1,30 - -
AC092656 unknown Homo sapiens BAC clone RP11-455G16 from 4, complete sequence. 1,26 1,17 -
AL080172 FLJ21919 hypothetical protein FLJ21919 1,24 - -
AK026024 FLJ10307 hypothetical protein FLJ10307 1,23 - -
AL048871 unknown DKFZp434I1018_r1 434 (synonym: htes3) Homo sapiens cDNA cloneDKFZp434I1018, mRNA sequence. 1,20 - -
BG575061 unknown 602598169F1 NIH_MGC_87 Homo sapiens cDNA clone IMAGE:4706800 5',mRNA sequence. 1,20 - -
BG685745 unknown 602637842F1 NIH_MGC_48 Homo sapiens cDNA clone IMAGE:4765403 5',mRNA sequence. 1,18 - -
G28534 unknown human STS SHGC-31555, sequence tagged site. 1,18 - -
AK026087 C9orf25 Homo sapiens cDNA: FLJ22434 fis, clone HRC09178, highly similar to AF131828 Homo sapiens clone 25012 mRNA sequence 1,17 - -
AF161555 unknown Homo sapiens HSPC070 mRNA, complete cds. 1,16 - -
AW897805 unknown RC1-NN0063-100500-022-c06 NN0063 Homo sapiens cDNA, mRNA sequence. 1,16 - -
AW962770 unknown EST374843 MAGE resequences, MAGG Homo sapiens cDNA, mRNA sequence. 1,15 - -
ESTs or Hypothetical proteins: 23,3%
Signal transduction
Transport (glucose, protein, ion ...)
Translation/ Protein biosynthesis
Other functions or unknown functions




